Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,626 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer Genetics Clear all

Conditions: Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions: Not listed
Lead sponsor: Global Healthy Living Foundation; Other
Eligibility: 19 Years and older
Enrollment: 40,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Upper Nyack, New York

Conditions: Chlamydia Trachomatis Infection, Gonorrhea
Interventions: Ct/GC screening; Other
Lead sponsor: Tulane University; Other
Eligibility: 15 Years to 26 Years · Male only
Enrollment: 1,907 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Hemangioblastoma, Hippel Lindau Disease
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 8 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: EBV-positive Nasopharyngeal Carcinoma
Interventions: DNR.NPC-specific T cells, DNR.NPC-specific T cells + cyclophosphamide + fludarabine; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2033
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
Interventions: FR901228; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Head and Neck Neoplasms
Interventions: Not listed
Lead sponsor: Montefiore Medical Center; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2030
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Neoplastic Syndrome
Interventions: tazarotene; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 2
States / cities: Oakland, California • New York, New York

Conditions: Breast Cancer, Advanced Solid Tumors, Cowden Syndrome
Interventions: BEZ235; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 9
States / cities: Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 6 more

Conditions: Pain
Interventions: SMART app wearable; Other
Lead sponsor: Duke University; Other
Eligibility: 8 Years to 80 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 35 Years to 64 Years
Enrollment: 9,257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Amyloidosis
Interventions: Melphalan, Autologous Stem Cell Transplantation; Drug · Procedure
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Hodgkin Lymphoma, Lymphoma Non-Hodgkin, B-cell Lymphoma, Immune Dysregulation
Interventions: Not listed
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 4 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Bethesda, Maryland • Portsmouth, Virginia

Conditions: Prostate Cancer
Interventions: Walk with Ease; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 65 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Fanconi Anemia, Head and Neck Cancer, Squamous Cell Carcinoma, Squamous Cell Cancer of Head and Neck (SCCHN)
Interventions: Metformin, Naproxen Sodium; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Minneapolis, Minnesota • New York, New York

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Trastuzumab Emtansine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lynch Syndrome
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2054
U.S. locations: 2
States / cities: Aurora, Colorado • Chicago, Illinois

Conditions: Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: Not listed
Enrollment: 726 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Sickle Cell, Diabetes, Cancer, Cardiovascular Disease, Genetic Screening
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 1,061 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 3
States / cities: Bethesda, Maryland • Cincinnati, Ohio • Lewisburg, Pennsylvania

Conditions: Neurofibromatosis Type 1, Plexiform Neurofibroma
Interventions: Binimetinib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Year and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more

Conditions: Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenia (CM)
Interventions: 3,4-diaminopyridine; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 2 Years and older
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Tuberous Sclerosis Complex
Interventions: JASPER; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 12 Months to 36 Months
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome, Breast Ductal Carcinoma In Situ, Hematopoietic and Lymphoid System Neoplasm, Hereditary Neoplastic Syndrome, Lynch Syndrome, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Genetic Counseling, Genetic Testing, Survey Administration; Procedure · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 27,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Neurofibromatosis 1
Interventions: Peg-Interferon alpha-2b, Celecoxib (Celebrex), Temozolomide (temodar), Vincristine Sulfate (Oncovin); Drug
Lead sponsor: Corewell Health West; Other
Eligibility: 2 Years to 30 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Gastroesophageal Junction Carcinoma, Uterine Cervical Neoplasms, Testicular Neoplasms
Interventions: SGN-ALPV; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Fresno, California • New Haven, Connecticut • Wellington, Florida + 4 more

Search by objective public record fields.

PatientSpot Formerly Known as ArthritisPower

Check it: A New Approach to Controlling Chlamydia Transmission in Young People

Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease

TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC

FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

Molecular and Genomic Profiling of Head and Neck Tumors

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Patient-Empowered Mobile Technology in Hospitalized Patients (TRU-PAIN)

Analysis of Data From the Women's Contraceptive and Reproductive Experiences (CARE) Study

Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis

Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma

Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer

Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Lynch Syndrome Integrative Epidemiology and Genetics

Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes

Developing the Family Map: Looking at Communal Coping

Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex

Identifying and Caring for Individuals With Inherited Cancer Syndrome

Medical Treatment of "High-Risk" Neurofibromas

A Study of SGN-ALPV in Advanced Solid Tumors